Tarcocimab and Tabirafusp Meet Phase 3 Endpoints

At AAO 2026, Charles C. Wykoff, MD, PhD, presented positive DAYBREAK results for both Kodiak Sciences agents. A BLA submission for tarcocimab is planned later this year.

By Jim Gallagher, senior managing editor

Early ELAAVATE Data Show Promise in DME

Arshad M. Khanani, MD, FASRS, discusses preliminary safety and efficacy findings from a phase 2 study of subretinal sura-vec gene therapy.

By Arshad M. Khanani, MD, MA, FASRS, Diana V. Do, MD

Remigromig Meets Primary Endpoint in BRUNELLO Trial

Both doses of the Wnt pathway agonist met the primary noninferiority endpoint in evaluation against ranibizumab in patients with DME, Donald J. D’Amico, MD, reported at AAO.

By Jim Gallagher, senior managing editor

FDA Accepts Vamikibart BLA for Uveitic Macular Edema

New phase 3 data presented at AAO 2026 showed sustained visual and anatomic improvements through 52 weeks in the MEERKAT and SANDCAT trials.

By Jim Gallagher, senior managing editor

Topcon Launches Oku Digital Health at AAO

Daniela Ferrara, MD, PhD, discusses Topcon's new oculomics initiative and the potential of retinal imaging to help identify systemic diseases.

By Daniela Ferrara, MD, PhD

K8 Shows Greater GA Growth Reduction Over Time

Liangbo Shen, MD, reported additional phase 2 findings at AAO 2026 as Inflammasome Therapeutics prepares for a phase 3 trial.

By Jim Gallagher, senior managing editor

Two-Year PRISM Data Show Reduced Treatment Burden

Veeral Sheth, MD, discusses the durability, safety, and supplemental injection requirements of intravitreal 4D-150 gene therapy for wet AMD.

By Veeral S. Sheth, MD, MBA, FACS, Diana V. Do, MD

What to Expect at AAO Retina Subspecialty Day

Subspecialty Day program co-chair Diana V. Do, MD, previews the clinical, surgical, and trial-focused programming planned for the upcoming AAO meeting in New Orleans.

By Diana V. Do, MD

Oculis CEO Outlines Phase 3 PIONEER Program

Riad Sherif, MD, discusses the development of privosegtor for optic neuritis and nonarteritic anterior ischemic optic neuropathy.

By Riad Sherif, MD

Three-Year MCO-010 Outcomes From RESTORE

Long-term findings presented in New Orleans suggest sustained visual function improvements in patients with advanced retinitis pigmentosa.

By Ramiro S. Maldonado, MD

AAVantgarde Presents New Usher Syndrome Gene Therapy Data

Updated results from the LUCE-1 trial show no serious adverse events or dose-limiting toxicities, with early signals of improved visual acuity.

By Natalia Misciattelli, PhD, Jayashree Sahni, MD, FRCOphth, PhD, EMBA

Behind the Scenes of Trials InSight

Drs. Minaker and Sambhara discuss the motivation behind their upcoming virtual meeting and its emphasis on collaboration across clinical research.

By Samuel Minaker, MD, MSc, Deepak Sambhara, MD, FASRS

The Challenges of Bringing Retinal Therapies to Market

At Eyecelerator 2026 in New Orleans, industry leaders discussed the clinical, regulatory, and commercial considerations shaping the next generation of retinal treatments.

By Jim Gallagher, senior managing editor

The Science Behind Optogenetics

Nanoscope Therapeutics cofounder Samarendra Mohanty, PhD, discusses the development of MCO-010, the challenges of engineering light sensitivity, and unexpected findings from clinical trials.

By Samarendra Mohanty, PhD

Assessing PRIMA’s Efficacy and Safety at 36 Months

Long-term results from the PRIMAvera study show approximately 30 letters of mean visual acuity improvement at 36 months, with most serious adverse events occurring early after surgery.

By Ehsan Rahimy, MD